Medtronic details diabetes facility warning letter

September 27, 2013 by Brad Perriello

Medtronic says a Sept. 19 warning letter from the FDA, revealed earlier today, stemmed from an inspection of a diabetes facility inspected as part of the pre-market approval process for its MiniMed 530G artificial pancreas.

Medtronic details diabetes facility warning letter

An FDA warning letter to Medtronic (NYSE:MDT), revealed earlier today along with pre-market approval for the MiniMed 530G artificial pancreas, concerned the medical device company's Northridge, Calif., diabetes facility, a spokeswoman told today.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.


Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp